IPF

View All

PDE4-B Inhibitors: A Promising Target for Idiopathic Pulmonary Fibrosis Treatment

Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...

Find More

Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) – When to start and what is coming in the race to treat the deadlier constricts….

Idiopathic Pulmonary Fibrosis (IPF) is a debilitating, chronic, fatal disease with an excess fibrous tissue called as fibrosis in the lungs. The idiopathic (unknown cause) character of the disease make it difficult to predict and treat in the initial stages. The irreversible damaging of lungs supporting frame work, ...

Find More

BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create the largest patient registry for Idiopathic Pulmonary Fibrosis (IPF) The IPF-PRO Registry will be widened to cover 1500 patients spread over 45 clinical sites which will stimulate understand...

Find More